HC Wainwright Raises Niagen Bioscience (NASDAQ:NAGE) Price Target to $12.00

Niagen Bioscience (NASDAQ:NAGE) had its target price hoisted by equities researchers at HC Wainwright from $11.00 to $12.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 16.96% from the company’s previous close.

NAGE has been the subject of a number of other research reports. Roth Capital reiterated a “buy” rating and issued a $23.00 price objective (up previously from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th. Canaccord Genuity Group upped their price objective on Niagen Bioscience from $13.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, June 10th. Finally, Wall Street Zen downgraded Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 2nd. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $13.42.

Niagen Bioscience Stock Up 4.5%

NAGE stock opened at $10.26 on Monday. The company has a market cap of $818.27 million, a P/E ratio of 48.86 and a beta of 2.12. Niagen Bioscience has a twelve month low of $2.81 and a twelve month high of $14.69. The business has a fifty day moving average of $11.70 and a 200-day moving average of $8.35.

Niagen Bioscience (NASDAQ:NAGE) last released its earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. The company had revenue of $31.12 million during the quarter, compared to the consensus estimate of $28.55 million. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Wyoming acquired a new position in Niagen Bioscience in the fourth quarter valued at about $39,000. Mercer Global Advisors Inc. ADV acquired a new position in Niagen Bioscience in the fourth quarter valued at about $53,000. Schonfeld Strategic Advisors LLC acquired a new position in Niagen Bioscience in the fourth quarter valued at about $67,000. ProShare Advisors LLC acquired a new position in Niagen Bioscience in the fourth quarter valued at about $74,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in Niagen Bioscience in the fourth quarter valued at about $94,000. 15.41% of the stock is owned by institutional investors and hedge funds.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.